ReviewJournal of fungi (Basel, Switzerland)2018
Therapy of Mucormycosis.
Review in Journal of fungi (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Coronavirus disease 2019-associated mucormycosis and cytomegalovirus infection: a case report.Journal of medical case reports · 2026Article
- Invasive tracheal mucormycosis causing irreversible glottic closure and long-term tracheostomy dependence: a case report and airway-centered management implications.Frontiers in medicine · 2026Article
- Rhino-Orbital-Cerebral Mucormycosis Complicated by Vision Loss in a Patient with Uncontrolled Diabetes: A Case Report.Microorganisms · 2025Article
- Survival and prognostic factors in rhino-orbito-cerebral mucormycosis: A 3-year cohort study.Scientific reports · 2025Article
- Rhino-Orbital Mucormycosis With Delayed Diagnosis in an Immunocompromised Patient: A Case Report.Cureus · 2025Article
- Case Report: Fiberoptic bronchoscopy and thoracoscopic surgery as a treatment for pulmonary mucormycosis in pediatric acute lymphoblastic leukemia.Frontiers in pediatrics · 2025Article
- Clinical performance of metagenomic next-generation sequencing for distinction and diagnosis ofFrontiers in cellular and infection microbiology · 2025Article
- Immune-modulating therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) in refractory rhino-orbital-cerebral mucormycosis - a case report.Frontiers in immunology · 2025Article
- Challenges in Management of Disseminated Mucormycotic Infection with Endocarditis in an Adult Patient Receiving Liver Transplantation.Infection and drug resistance · 2025Article
- Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections.Current drug targets · 2025Review
- Mucormycosis after liver transplant: Case series and literature review.Medical mycology case reports · 2024Article
- Functional Rehabilitation - an Integral Component for Quality of Life in the Holistic Management of COVID-19 Associated Mucormycosis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.Annals of medicine · 2024Review
- Article
- A clinical study of rhino-orbital-cerebral mucormycosis during the COVID-19 pandemic in western Maharashtra.Journal of family medicine and primary care · 2024Article
- Mucormycosis during COVID-19 era: A retrospective assessment.Infectious medicine · 2024Review
- Development of a Combat-Relevant Murine Model of Wound Mucormycosis: A Platform for the Pre-Clinical Investigation of Novel Therapeutics for Wound-Invasive Fungal Diseases.Journal of fungi (Basel, Switzerland) · 2024Article
- From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis.Diagnostics (Basel, Switzerland) · 2024Review
- Clinical features of pediatric mucormycosis: role of metagenomic next generation sequencing in diagnosis.Frontiers in cellular and infection microbiology · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the recent introduction of mold-active agents (posaconazole and isavuconazole), in addition to amphotericin B products, to our armamentarium against mucormycosis, many uncertainties remain for the management of this uncommon opportunistic infection, as there are no data from prospective randomized clinical trials to guide therapy. In this mini-review, we present the current status of treatment options. In view of the heterogeneity of the disease (different types of affected hosts, sites of infection, and infecting Mucorales), mucormycosis management requires an individualized management plan that takes into account the net state of immunosuppression of the host, including comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.